CTMC

Activities: Research & Development

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Cell & Gene Therapy

CTMC and Einstein Hospital Israelita form global alliance to expand access to cell therapy

The new CTMC Network Alliance will accelerate the adoption of cell and gene therapies across Latin America, aiming to make life-saving treatments more accessible through shared expertise, training and manufacturing innovation

CTMC appoints Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer
Manufacturing

Investing in a manufacturing infrastructure to harness tumour-infiltrating lymphocytes (TILs) for cancer treatment

In this article, Dr Chantale Bernatchez, Director of Process Development at CTMC, highlights the need for a standardised TIL manufacturing process that facilitates co-ordination between labs, clinics and production sites. She emphasises the value of using the lessons learned from implementing CAR-T therapy to streamline the introduction of new TIL treatments to the patients who need them
Subscribe now